Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...
The race for the next Ozempic is on
Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...